posaconazole, sold under the brand names noxafil and posanol is a triazole antifungal medication.
it was approved for medical use in the united states in september 2006, and is available as a generic medication.
posaconazole is used to treat invasive aspergillus and candida and fungal infections caused by scedosporium and fusarium species, which may occur in immunocompromised patients. it is also used for the treatment of oropharyngeal candidiasis (opc), including opc refractory to itraconazole and/or fluconazole therapy.
it is also used to treat invasive infections by candida, mucor, and aspergillus species in severely immunocompromised patients.
clinical evidence for its utility in treatment of invasive disease caused by fusarium species (fusariosis) is limited.
it appears to be helpful in a mouse model of naegleriasis.